A3 Adenosine and P2X7 Purinergic Receptors as New Targets for an Innovative Pharmacological Therapy of Malignant Pleural Mesothelioma

A3 Adenosine and P2X7 Purinergic Receptors as New Targets for an Innovative Pharmacological Therapy of Malignant Pleural Mesothelioma

Human malignant pleural mesothelioma (MPM) is a rare, but aggressive tumor of the serosal cavities whose 5-year survival rate is 15%. At present, there are no effective therapies for MPM. Although recent findings suggest that A3 adenosine (A3AR) and P2X7 (P2X7R) receptors can be employed as antitumo...

Full description

Bibliographic Details
Main Authors: Fabrizio Vincenzi, John Charles Rotondo, Silvia Pasquini, Francesco Di Virgilio, Katia Varani, Mauro Tognon
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-10-01
Series:Frontiers in Oncology
Subjects:
malignant pleural mesothelioma
A3 adenosine receptor
P2X7 receptor
Cl-IB-MECA
AZ10606120
anticancer therapy
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2021.679285/full

Similar Items

Similar Items